Schedule of Suraksha Diagnostic
| Issue open date | 29 Nov 2024 |
| Issue close date | 03 Dec 2024 |
| UPI mandate deadline | 03 Dec 2024 (5 PM) |
| Allotment finalization | 04 Dec 2024 |
| Refund initiation | 05 Dec 2024 |
| Share credit | 05 Dec 2024 |
| Listing date | 06 Dec 2024 |
| Mandate end date | 18 Dec 2024 |
| Lock-in end date for anchor investors (50%) | 03 Jan 2025 |
| Lock-in end date for anchor investors (remaining) | 04 Mar 2025 |
Note: The schedule is tentative. The anchor lock-in period ends 30 days after the actual allotment date for 50% of the shares and 90 days after for the remaining portion. The allotment status can be checked on the registrar's website and the exchange website.
About Suraksha Diagnostic
Suraksha Diagnostic Limited, incorporated in 2005, operates as an integrated diagnostic service provider in East India, covering pathology, radiology, and medical consultation. With central reference and satellite labs, along with diagnostic centres, the company provides accessible diagnostic services, accredited by the College of American Pathologists and NABL, across regions including West Bengal, Bihar, Assam, and Meghalaya.
Financials of Suraksha Diagnostic
Strengths
- Leading presence in eastern India’s diagnostic market with growth potential in a fragmented industry.
- Provides comprehensive diagnostics, including pathology, radiology, and consultations.
- Equipped with advanced clinical infrastructure and skilled personnel for reliable services.
- Recognized brand with a focus on quality, supporting individual consumer business.
Risks
- The company’s business relies heavily on West Bengal, and any loss of business in this region may negatively impact overall performance.
- Keeping up with new tests and technology is essential; falling behind could weaken the company’s competitive edge.
- The company depends on third-party vendors for testing equipment, and supply disruptions could affect operations.
- Franchisees run many collection centres, and failing to meet the required standards could impact quality and reputation.
- The diagnostics industry is highly competitive, which could lead to price cuts that affect profits.
- The company has significant debt and financial agreements that may reduce flexibility and affect financial health.
Subscription Figures for Suraksha Diagnostic
Subscription numbers as of 5:00 PM on 3 Dec 2024:
| Category | Shares Reserved | Shares Bid | Subscription (No. of times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIBs) | 38,37,867 | 66,67,332 | 1.74 |
| Non Institutional Investors | 28,78,400 | 40,42,124 | 1.40 |
| Retail Individual Investors (RIIs) | 67,16,266 | 62,99,078 | 0.94 |
| Total | 1,34,32,533 | 1,70,08,534 | 1.27 |